Ram Isanaka-FOUNDED ISSAR PHARMACEUTICALS-to develop new peptide molecules addressing the unmet healthcare needs.
ISSAR conducted the FIRST HUMAN CLINICAL TRIALS FOR MELGAIN (phase 1). ISSAR was the first and the only company to have conducted phase 1 clinical trial in India since independence.
ISSAR commercialised the first ever peptide solution for Vitiligo.
MELGAIN was launched into the market for the treatment of VITILIGO by Dr. Reddy’s in India.
ISSAR pharmaceuticals established their state-of-the-art, FDA-compliant, 62000 sq ft., manufacturing facility at Genome Valley, Hyderabad, India.
Successfully completed Phase 1 clinical trial for cancers (solid tumors).
ISSAR successfully completed phase III clinical trials for BURN WOUNDS TREATMENT XYLENTRA.
ISSAR initiated new drug development for regulatory markets.
ISSAR got the DCGI approval for manufacturing NEW BULK SUBSTANCE XYLENTRA.
ISSAR obtained approval for manufacturing and marketing XYLENTRA.